<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02390986</url>
  </required_header>
  <id_info>
    <org_study_id>LON002-003</org_study_id>
    <nct_id>NCT02390986</nct_id>
  </id_info>
  <brief_title>An Extension Study of LON002 in Patients With Cancer</brief_title>
  <official_title>An Extension Study of LON002 in Patients With Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LondonPharma Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LondonPharma Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical trial is to evaluate the long term safety and efficacy of&#xD;
      LON002.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an extension study of LON002 in patients with cancer, who have completed other London&#xD;
      Pharma sponsored LON002 studies (parent study). It provides the opportunity for patients to&#xD;
      continue receiving treatment for as long as the patient continues to derive a clinical&#xD;
      benefit.&#xD;
&#xD;
      Long term safety and efficacy will be evaluated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with Adverse Events grade â‰¥3 related to LON002 and Serious Adverse Events related to LON002 as a measure of safety and tolerability.</measure>
    <time_frame>Participants will be followed for the duration of their study treatment, an expected average of 6 months</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Solid Tumours</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LON002</intervention_name>
    <description>Extension study to provide continuing access to LON002 medication.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent;&#xD;
&#xD;
          2. Has completed a LondonPharma sponsored parent trial of LON002 and continues to have&#xD;
             clinical benefit in the judgement of the investigator;&#xD;
&#xD;
          3. Eligible for continuation of LON002 treatment at the end of the parent trial,&#xD;
             according to the parent trial protocol;&#xD;
&#xD;
          4. Able to comply with the protocol LON002-003;&#xD;
&#xD;
          5. Women of child bearing potential must have a negative pregnancy test before the start&#xD;
             of treatment;&#xD;
&#xD;
          6. Sexually active women of childbearing potential must be using an acceptable form of&#xD;
             contraception for the duration of dosing and for 30 days thereafter;&#xD;
&#xD;
          7. Male subjects with female partners of childbearing potential should use condoms for&#xD;
             the duration of dosing and for 30 days thereafter&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Has not completed a LondonPharma sponsored parent trial of LON002;&#xD;
&#xD;
          2. Unequivocal evidence of disease progression;&#xD;
&#xD;
          3. Unacceptable toxicity experienced in the parent trial;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Debashis Sarker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guy's and St Thomas' NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mazhar Ajaz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Surrey County Hospital NHS Trust</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daryl Bendel, MD</last_name>
    <role>Study Director</role>
    <affiliation>Xidea Solutions Ltd</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Laskow-Pooley</last_name>
    <phone>01865 784485</phone>
    <email>davidlaskow-pooley@londonpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Royal Surrey County Hospital</name>
      <address>
        <city>Guildford</city>
        <state>Surrey</state>
        <zip>GU2 7XX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Mazhar Ajaz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guy's and St Thomas NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Debashis Sarker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>March 2, 2015</study_first_submitted>
  <study_first_submitted_qc>March 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2015</study_first_posted>
  <last_update_submitted>March 11, 2015</last_update_submitted>
  <last_update_submitted_qc>March 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>Malignant Neoplasm</keyword>
  <keyword>Anti-cancer drug</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

